CA
NZ
UK
AU
IND
US
…
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 |
| Income before tax | -57.50M | -67.86M | 24.65M | 54.52M | 60.53M |
| Minority interest | - | -0.54M | 0.51M | 0.53M | 0.03M |
| Net income | -59.73M | -68.49M | 16.34M | 41.42M | 47.81M |
| Selling general administrative | 49.73M | 51.35M | 66.44M | 21.17M | 58.54M |
| Selling and marketing expenses | 29.03M | 14.91M | 38.92M | 72.89M | 34.10M |
| Gross profit | 44.36M | 99.75M | 157.76M | 166.78M | 173.61M |
| Ebit | -54.97M | -3.55M | 30.37M | 58.76M | 88.91M |
| Ebitda | -45.76M | 8.92M | 43.46M | 73.27M | 99.45M |
| Depreciation and amortization | 9.22M | 12.47M | 13.09M | 14.51M | 10.55M |
| Operating income | -54.97M | -3.55M | 30.37M | 58.76M | 88.91M |
| Other operating expenses | 200.07M | 214.98M | 275.57M | 237.39M | 188.06M |
| Interest expense | 5.83M | 6.61M | 5.90M | 5.75M | 28.37M |
| Non recurring | 38.45M | 56.45M | 56.45M | - | - |
| Income tax expense | 2.22M | 0.64M | 8.34M | 13.22M | 12.73M |
| Total revenue | 145.10M | 212.69M | 305.94M | 296.15M | 264.64M |
| Total operating expenses | 99.33M | 102.04M | 127.39M | 108.02M | 97.03M |
| Cost of revenue | 100.74M | 112.94M | 148.19M | 129.37M | 91.03M |
| Total other income expense net | -2.53M | -64.31M | -5.72M | -4.24M | -28.37M |
| Net income from continuing ops | -59.73M | -68.49M | 14.06M | 41.30M | - |
| Net income applicable to common shares | -59.71M | -67.45M | 14.09M | 41.42M | 47.06M |
| Breakdown | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 |
| Total assets | 446.31M | 564.98M | 611.54M | 576.48M | 524.05M |
| Intangible assets | 175.87M | 168.66M | 170.32M | 172.30M | 172.68M |
| Other current assets | 0.72M | 5.17M | 2.99M | 1.25M | 10.74M |
| Total liab | 118.72M | 183.82M | 180.64M | 181.43M | 178.19M |
| Total stockholder equity | 327.59M | 381.70M | 430.40M | 394.52M | 345.21M |
| Deferred long term liab | 0.21M | 1.35M | 2.36M | 3.29M | - |
| Other current liab | 26.69M | 20.50M | 6.28M | 2.20M | 22.44M |
| Common stock | 0.52M | 0.37M | 0.08M | 0.08M | 0.08M |
| Retained earnings | 78.10M | 137.81M | 207.52M | 191.17M | 149.92M |
| Other liab | 11.96M | 14.57M | 21.89M | 18.71M | - |
| Good will | - | - | 33.16M | 33.16M | 28.54M |
| Other assets | 17.71M | 23.94M | 10.87M | 11.42M | 11.88M |
| Cash | 7.10M | 52.63M | 94.57M | 91.13M | 70.64M |
| Total current liabilities | 106.21M | 159.78M | 44.08M | 46.97M | 46.04M |
| Current deferred revenue | 1.42M | 1.38M | 19.52M | 23.44M | 0.85M |
| Net debt | 60.55M | 63.81M | 28.67M | 38.45M | 55.90M |
| Short term debt | 67.09M | 115.82M | 7.56M | 13.84M | 10.46M |
| Short long term debt | 49.23M | 108.56M | 0.06M | 0.06M | - |
| Short long term debt total | 67.64M | 116.44M | 123.24M | 129.58M | 126.54M |
| Other stockholder equity | 177.17M | 175.79M | 173.67M | 170.22M | 195.74M |
| Property plant equipment | 171.38M | 170.53M | 132.06M | 124.44M | 123.54M |
| Total current assets | 95.45M | 195.91M | 206.25M | 177.92M | 132.45M |
| Long term investments | 3.34M | 5.93M | 19.18M | 57.24M | - |
| Net tangible assets | 169.15M | 213.04M | 224.58M | 189.06M | - |
| Short term investments | 6.51M | 0.26M | 0.54M | 3.30M | - |
| Net receivables | 50.23M | 99.20M | 80.60M | 57.50M | 37.69M |
| Long term debt | 0.55M | 0.62M | 115.68M | 115.74M | 116.08M |
| Inventory | 20.57M | 18.89M | 12.67M | 10.02M | 13.04M |
| Accounts payable | 11.01M | 22.09M | 10.72M | 7.50M | 12.29M |
| Accumulated other comprehensive income | 71.79M | 67.72M | 49.13M | 33.05M | -0.54M |
| Preferred stock total equity | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Treasury stock | -0.80M | -0.80M | - | - | - |
| Non currrent assets other | 0.27M | 23.68M | 10.53M | 11.20M | 65.53M |
| Non current assets total | 350.86M | 369.07M | 405.29M | 398.56M | 391.60M |
| Breakdown | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 |
| Investments | 18.33M | 5.16M | -0.05M | -0.24M | - |
| Change to liabilities | -6.37M | 4.12M | 2.02M | -4.79M | - |
| Total cashflows from investing activities | 15.18M | -71.95M | -6.34M | -6.76M | - |
| Net borrowings | -7.96M | -3.74M | -6.63M | 1.08M | - |
| Total cash from financing activities | -15.49M | -4.26M | -3.87M | -3.22M | 80.95M |
| Change to operating activities | -2.57M | -4.90M | -2.97M | 1.69M | - |
| Net income | -59.73M | -68.49M | 16.31M | 41.30M | 47.81M |
| Change in cash | -45.53M | -41.94M | 3.44M | 23.79M | -95.77M |
| Begin period cash flow | 52.63M | 94.57M | 91.13M | 70.64M | 166.41M |
| End period cash flow | 7.10M | 52.63M | 94.57M | 94.42M | 70.64M |
| Total cash from operating activities | -46.45M | 29.96M | 8.03M | 25.41M | 77.76M |
| Depreciation | 12.03M | 12.47M | 12.70M | 12.44M | 10.55M |
| Other cashflows from investing activities | 23.17M | -27.85M | -0.02M | 6.40M | - |
| Change to inventory | -4.25M | -3.00M | -2.64M | 3.15M | 0.75M |
| Change to account receivables | -2.58M | 15.79M | -30.33M | -20.53M | - |
| Sale purchase of stock | -1.27M | -0.80M | -0.80M | - | - |
| Other cashflows from financing activities | 12.66M | 0.27M | 6.76M | 10.68M | 80.95M |
| Change to netincome | 7.71M | 71.84M | 3.88M | -0.19M | - |
| Capital expenditures | 26.14M | 49.87M | 6.08M | 5.10M | 172.68M |
| Change in working capital | -7.17M | 12.19M | -24.56M | -29.19M | 0.61M |
| Stock based compensation | 2.81M | 3.21M | 3.20M | 2.63M | 1.64M |
| Other non cash items | 4.85M | 76.44M | 0.78M | -0.80M | 12.91M |
| Free cash flow | -72.60M | -19.92M | 1.95M | 20.31M | -94.92M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.
1 First Liangshuihe Avenue, Beijing, China, 100176
86 10 5982 2039
3719
| Name | Title | Year Born |
|---|---|---|
| Mr. Shujun Liu | Founder, Chairman, Chief Exec. Officer and Pres | 1953 |
| Ms. Yanchun Li | Founder, Chief Financial Officer, Sec. and Director | 1969 |
| Mr. Jun Min | Founder, VP, Gen. Mang. of HSPL and Director | 1959 |
| Mr. Xiaopeng Xu | Chief Operating Officer | 1949 |
| Mr. Lawrence S. Wizel | Financial Consultant | 1943 |
| Mr. Yan Gao | Chief Accounting Officer | 1972 |
| Yongxin Zhou | Director of Sales | NA |
| Ziyun Zhou | Gen. Mang. of HR | NA |
| Xiaoliang Wang | Pres of R&D | NA |
| Mr. Shujun Liu | Founder, Chairman, Chief Executive Officer and President | 1953 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...